Western Oncolytics was founded in 2014 to bring cutting-edge, next-generation oncolytic immunotherapies to cancer patients everywhere. Spun out of University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs, our company is now advancing multiple therapeutic candidates towards the clinic and occupies over 18,000 square feet of lab space in our Pittsburgh headquarters. We are engineering an optimized vaccinia virus-based oncolytic platform which can be combined with multiple transgenes to create versatile and differentiated immunotherapies. Our development programs are designed to be safe, potent, and systemically deliverable to treat cancer patients across a variety of tumor types. In 2016, we formed a strategic partnership with Pfizer for our lead preclinical program, WO-12.